Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049113 · ClinicalTrials.gov registry record · Phase 1
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
A Phase 1 study, sponsored by Traws Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01049113 is a Phase 1 study that was terminated before completion, run by Traws Pharma. The registered enrollment target is 7 participants.
The verdict
NCT01049113, a Phase 1 study, was terminated before completion, sponsored by Traws Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity. The purpose of this study is to determine the highest dose of ON 013105 that can be given safely in patients with relapsed/refractory Lymphoma or B-cell Acute Lymphocytic Leukemia (Philadelphia chromosome negative). Patients will receive weekly 2-hour IV infusions of ON 013105 at higher and higher doses until intolerable side effects are observed. It is important to know the highest safe dose so additional studies can be done.
Interventions
- DRUG ON 013105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049113
The ClinicalTrials.gov registry entry for NCT01049113 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ON 013105 is the first listed.
NCT01049113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01049113 about?
NCT01049113 is a clinical study titled "Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia". This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105. In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity. The purpose of this study is to determine the highest dose of ON 013105 that can be given safely in patients with relapsed/refr...
What is the current status of trial NCT01049113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01049113?
The interventions under investigation include: ON 013105 (DRUG).
Who is sponsoring clinical trial NCT01049113?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.